Fetching results...
0 items found

PT165: Outcomes of early vs. delayed combination medical therapy in LUTS/BPH patients with moderate to severe symptoms: Results from clinical trial simulations using individual IPSS trajectories

Della Pasqua O. 1 , D'Agate S. 2 , Adalig B. 3 , Wilson T. 4 , Chavan C. 5 , Manyak M. 6 , Palacios-Moreno J.M. 7 , Oelke M. 8 , Roehrborn C. 9
1GlaxoSmithKline, Dept. of Urology, London, United Kingdom, 2University College London, Clinical Pharmacology and Therapeutics Group, London, United Kingdom, 3GlaxoSmithKline, Dept. of Urology, Istanbul, Turkey, 4PAREXEL International, Dept. of Statistics, Durham, United States of America, 5GlaxoSmithKline, Dept. of Urology, Mumbai, India, 6GlaxoSmithKline, Dept. of Urology, Washington, United States of America, 7GlaxoSmithKline, Dept. of Urology, Madrid, Spain, 8St. Antonius Hospital, Dept. of Urology, Gronau, Germany, 9University of Texas Southwestern Medical Center, Dept. of Urology, Texas, United States of America, 10
34th Annual EAU Congress (EAU19)
Date – time - Location
16 March 2019, 15:30 - 17:30, Green Area, Room B
Expert-Guided Poster Tour 07 - Benign prostatic enlargement management
BPH: Research, Diagnosis and treatment
  • © 2021 European Association of Urology
  • Disclaimer